## Helga Simon-Molas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8345145/publications.pdf

Version: 2024-02-01

1478505 1588992 8 311 6 citations h-index g-index papers

8 8 8 665 docs citations times ranked citing authors all docs

8

#	Article	IF	CITATIONS
1	<scp>TGF</scp> â€Î²1 targets Smad, p38 <scp>MAPK</scp> , and <scp>PI</scp> 3K/Akt signaling pathways to induce <scp>PFKFB</scp> 3 gene expression and glycolysis in glioblastoma cells. FEBS Journal, 2017, 284, 3437-3454.	4.7	116
2	Fructose 2,6-Bisphosphate in Cancer Cell Metabolism. Frontiers in Oncology, 2018, 8, 331.	2.8	83
3	The potential utility of PFKFB3 as a therapeutic target. Expert Opinion on Therapeutic Targets, 2018, 22, 659-674.	3.4	54
4	PI3K–Akt signaling controls PFKFB3 expression during human T-lymphocyte activation. Molecular and Cellular Biochemistry, 2018, 448, 187-197.	3.1	19
5	Akt mediates <scp>TIGAR</scp> induction in HeLa cells following <scp>PFKFB</scp> 3 inhibition. FEBS Letters, 2016, 590, 2915-2926.	2.8	16
6	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. Blood, 2022, 140, 630-643.	1.4	14
7	TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Is Upregulated in Lymphocytes Stimulated with Concanavalin A. International Journal of Molecular Sciences, 2021, 22, 7436.	4.1	5
8	The Expression of TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Can Be Controlled by the Antioxidant Orchestrator NRF2 in Human Carcinoma Cells. International Journal of Molecular Sciences, 2022, 23, 1905.	4.1	4